© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to August
oral FXR agonist for NASH
robust in vivo PD, phase I HV study withdrawn
from prior FXR agonists
ACS Med. Chem. Lett
Bristol Myers Squibb, Princeton, NJ, USA
The BMS spirocyclobutene-containing FXR agonist, BMS-986318, appears to have been intended as a clinical candidate, but was withdrawn from a planned Ph. I study. The molecule exhibits potent in vitro and in…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.